Canada Life
MRSN

Canada Life’s Mersana Therapeutics MRSN Stock Holding History

Canada Life’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,782
Closed -$56K – 2200
2023
Q3 		$56K Hold
1,782
– – ﹤0.01% 2056
2023
Q2 		$147K Hold
1,782
– – ﹤0.01% 1871
2023
Q1 		$184K Hold
1,782
– – ﹤0.01% 1881
2022
Q4 		$263K Buy
1,782
+877
+97% +$148K ﹤0.01% 1847
2022
Q3 		$153K Buy
905
+759
+520% +$123K ﹤0.01% 1916
2022
Q2 		$17K Hold
146
– – ﹤0.01% 2291
2022
Q1 		$15K Hold
146
– – ﹤0.01% 2398
2021
Q4 		$23K Hold
146
– – ﹤0.01% 2347
2021
Q3 		$34K Hold
146
– – ﹤0.01% 2331
2021
Q2 		$49K Hold
146
– – ﹤0.01% 2278
2021
Q1 		$58K Hold
146
– – ﹤0.01% 2250
2020
Q4 		$96K Hold
146
– – ﹤0.01% 2116
2020
Q3 		$68K Hold
146
– – ﹤0.01% 2116
2020
Q2 		$84K Buy
+146
New +$49.9K ﹤0.01% 2096

Other funds holding MRSN

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Canada Life's MRSN Position: Q4 2023 in Review

Canada Life sold out of Mersana Therapeutics (MRSN) in Q4 2023, closing a stake of 1,782 shares — an estimated $56K sold.

Canada Life first reported a position in MRSN in Q2 2020 and held it in 14 quarters. The position peaked at $263K in Q4 2022. 105 funds tracked by Wall St. Rank hold MRSN as of Q4 2023.

  • Canada Life reported no remaining Mersana Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Canada Life sold 1,782 Mersana Therapeutics shares in Q4 2023, an estimated $56K.
  • Canada Life first reported a position in Mersana Therapeutics in Q2 2020 and held it in 14 quarters.
  • Canada Life's Mersana Therapeutics position peaked at $263K in Q4 2022.
  • 105 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q4 2023.

Based on Canada Life's 13F filing for Q4 2023, filed 13 Feb 2024.